Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances-Reference-Cited by-同舟云学术

Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances

Published:2021-01 Issue:1 Volume:145 Page:42-51
ISSN:1347-8613
Container-title:Journal of Pharmacological Sciences
language:en
Short-container-title:Journal of Pharmacological Sciences

Author:

Inoue Yoshifumi,Tsuchimori Kimiko,Nakamura Hiroshi

Publisher

Elsevier BV

Subject

Pharmacology,Molecular Medicine

Reference66 articles.

1. Preclinical characteristic and clinical positioning of Blonanserin for schizophrenia;Murasaki;Jpn J Clin Psychopharmacol,2008

2. Clinical evaluation of Blonanserin for schizophrenia –A double-blind trial comparing Blonanserin with haloperidol;Murasaki;Jpn J Clin Psychopharmacol,2007

3. Clinical evaluation of Blonanserin for schizophrenia –A randomized study comparing Blonanserin with risperidone;Miura;Jpn J Clin Psychopharmacol,2008

4. Efficacy, tolerability, and safety of blonanserin in schizophrenia: an updated and extended systematic review and meta-analysis of randomized controlled trials;Kishi;Pharmacopsychiatry,2019

5. Clinical evaluation of aripiprazole in schizophrenic patients: a comparative double–blind study with haloperidol;Ishigooka;Jpn J Clin Psychopharmacol,2006

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning;BMC Psychiatry;2024-09-05

2. Translation from Preclinical Research to Clinical Trials: Transdermal Drug Delivery for Neurodegenerative and Mental Disorders;Pharmaceutical Research;2024-06

3. Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials;BMC Psychiatry;2023-10-11

4. Safety and effectiveness of oral blonanserin for schizophrenia in adolescents in China: Data from a 12-week post-marketing surveillance;The European Journal of Psychiatry;2023-10

5. Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance;BMC Psychiatry;2023-02-21